- Stocks
- Pharma & Healthcare
- Zim Laboratories
Zim Laboratories share price
NSE: ZIMLABPharma & HealthcareDrug Manufacturers - Specialty & Generic
Zim Laboratories at a glance
Zim Laboratories (NSE: ZIMLAB) closed at ₹133.50 on 22 Oct 2026, up 2.30% on the day. With a market capitalisation of ₹715 Cr, it ranks 1616th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 112.2× trailing earnings, against a return on equity of 2.0% in FY26. Over the past year the share price has risen 92.4%. Its 52-week range is ₹59.31 (30 Mar 2026) to ₹159.81 (12 Oct 2026); the last close is 16.5% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹94 Cr (+31.2% year on year) and net profit −₹4 Cr, on a consolidated basis. Promoters held 30.36% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹715 CrRank 1616 on NSE
- P/E (trailing)
- 112.2×
- Price to book
- 1.08×FY26
- EPS (TTM)
- ₹0.82to Q1 FY27
- ROE
- 2.0%FY26
- ROCE
- 6.1%FY26
- Debt to equity
- 0.42FY26
- Net profit margin
- 1.6%FY26
- Book value / share
- ₹55.36FY26
- 52-week high
- ₹159.8112 Oct 2026
- 52-week low
- ₹59.3130 Mar 2026
- 1-year return
- +92.4%
- RSI (14-day)
- 46.1
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +2.30% | −7.7% | −1.8% | +14.6% | +92.4% |
Zim Laboratories quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹92 Cr | ₹96 Cr | ₹109 Cr | ₹72 Cr | ₹89 Cr | ₹109 Cr | ₹105 Cr | ₹94 Cr |
| Revenue YoY | +7.4% | +0.0% | −7.7% | −12.3% | −3.7% | +12.8% | −3.2% | +31.2% |
| Net profit | ₹2 Cr | ₹4 Cr | ₹5 Cr | −₹2 Cr | −₹0 Cr | ₹4 Cr | ₹4 Cr | −₹4 Cr |
| Net profit YoY | −42.7% | −16.3% | −39.7% | −307.8% | −117.6% | +10.0% | −23.4% | — |
| Net margin | 2.6% | 4.2% | 4.5% | −2.6% | −0.5% | 4.0% | 3.6% | −4.3% |
| EPS | ₹0.49 | ₹0.82 | ₹1.01 | −₹0.38 | −₹0.09 | ₹0.90 | ₹0.76 | −₹0.75 |
Zim Laboratories financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹307 Cr | ₹333 Cr | ₹399 Cr | ₹367 Cr | ₹379 Cr | — |
| Operating profit | ₹15 Cr | ₹21 Cr | ₹35 Cr | ₹24 Cr | ₹18 Cr | — |
| Net profit | ₹7 Cr | ₹15 Cr | ₹24 Cr | ₹17 Cr | ₹12 Cr | — |
| EPS (₹) | ₹5.00 | ₹9.00 | ₹5.00 | ₹4.00 | ₹3.00 | — |
| Cash from operations | ₹32 Cr | ₹49 Cr | ₹38 Cr | ₹16 Cr | ₹41 Cr | — |
| Total debt | ₹22 Cr | ₹19 Cr | ₹25 Cr | ₹36 Cr | ₹40 Cr | ₹42 Cr |
| Shareholders' equity | ₹161 Cr | ₹176 Cr | ₹200 Cr | ₹239 Cr | ₹252 Cr | ₹296 Cr |
Zim Laboratories shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 13 Mar 2026 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 33.26% | 33.26% | 33.26% | 30.30% | 30.35% | 30.36% |
| Foreign institutions | 0.03% | — | 0.02% | 0.00% | — | 0.03% |
| Domestic institutions | 0.24% | 0.24% | 0.20% | 0.07% | 0.07% | 1.33% |
| Non-institutions | 66.46% | 66.51% | 66.52% | 69.63% | 69.58% | 68.28% |
Zim Laboratories vs peers
The listed Pharma & Healthcare companies nearest to Zim Laboratories by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| KILITCHKilitch Drugs (India) | ₹215.00 | −0.92% | +22.8% | ₹752 Cr | 24.2 | — |
| VIKRAMTHVikram Thermo | — | — | — | ₹728 Cr | — | — |
| ZIMLABZim Laboratories | ₹133.50 | +2.30% | +92.4% | ₹715 Cr | 112.2 | — |
| VALIANTLABValiant Laboratories | ₹131.05 | −2.00% | +56.4% | ₹712 Cr | — | — |
| AMANTAAmanta Healthcare | ₹182.55 | −3.26% | +37.4% | ₹709 Cr | 42.2 | — |
| GAUDIUMIVFGaudium IVF and Women Health | ₹95.11 | +1.07% | — | ₹692 Cr | 24.3 | — |
| WANBURYWanbury | ₹185.66 | −0.42% | −25.7% | ₹649 Cr | 9.6 | — |
Ask anything about Zim Laboratories
Pivot answers on the live chart with evidence you can check, and tests strategies against ZIMLAB's own history. Try: “Why has ZIMLAB moved over the last three months?” · “Backtest a 50-day moving-average crossover on ZIMLAB over five years” · “Compare ZIMLAB with KILITCH on margins and valuation”
Frequently asked questions about Zim Laboratories
What is the share price of Zim Laboratories today?
Zim Laboratories (NSE: ZIMLAB) last closed at ₹133.50 on 22 Oct 2026. Its 52-week high is ₹159.81 and its 52-week low is ₹59.31.
What is the market cap of Zim Laboratories?
Zim Laboratories' market capitalisation is ₹715 Cr (₹715 Cr) at the 22 Oct 2026 close, ranking 1616th among the NSE companies Pivot tracks.
What is the P/E ratio of Zim Laboratories?
Zim Laboratories trades at a trailing P/E of 112.2. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 24.3.
What is the ROE and ROCE of Zim Laboratories?
Return on equity was 2.0% in FY26 and return on capital employed was 6.1% in FY26 (consolidated figures).
Is Zim Laboratories a debt-free company?
No. Zim Laboratories' debt-to-equity ratio was 0.42 in FY26, with total debt of ₹42 Cr.
What were Zim Laboratories' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Zim Laboratories reported revenue of ₹94 Cr, +31.2% year on year, and net profit of −₹4 Cr.
How has Zim Laboratories stock performed over the last year?
Zim Laboratories' share price has risen 92.4% over the past year, +14.6% over three months and −1.8% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Zim Laboratories?
As of 30 Jun 2026: promoters 30.36%, foreign institutions 0.03%, domestic institutions 1.33%, non-institutions 68.28%.
Who are Zim Laboratories' competitors?
The listed Pharma & Healthcare companies closest to Zim Laboratories by market cap are Kilitch Drugs (India), Vikram Thermo, Valiant Laboratories, Amanta Healthcare, Gaudium IVF and Women Health and Wanbury.
Is Zim Laboratories a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Zim Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ZIMLAB against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with Z · all NSE stocks · this page as text